OptiScan Biomedical, a US-based intensive care monitoring technology provider backed by diversified conglomerate Mitsui, has received $20m in series E funding from undisclosed investors.
OptiScan has developed a bedside blood monitoring device called the OptiScanner 5000 which is used by clinicians to monitor glucose levels in critically ill patients in order to detect changes in their condition.
In addition to funding the commercialisation of the OptiScanner in the US, the series E funding will support the expansion of the company’s technology to monitoring additional substances.
Venture capital firm NGN Capital led a $36m funding round for the company in 2005 that included Mitsui and Ascension Health Ventures, which invests on behalf of care provider Ascension Health, as well as financial services firm Sanders Morris Harris, MedVenture Associates, Morgenthaler Ventures, Wellcome Trust, Prism Venture Partners and EGS Healthcare Capital Partners.
The same investors were joined by Wexford Capital for a $53m round in 2008, before OptiScan added $30.7m from Johnson & Johnson Innovation – JJDC, the corporate VC arm of Johnson & Johnson, as well as Medventure, Morgenthaler and Wexford Capital in 2013.
The company had also raised approximately $63.5m across three separate funding rounds in 2010, 2012 and 2016, according to regulatory filings.